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Background: After major abdominal surgery (MAS), 20 % of patients endure major complications, which require
invasive treatment and are associated with increased morbidity and mortality. A quality control algorithm after
major abdominal surgery aimed at early identification of patients at risk of developing major complications can
decrease associated morbidity and mortality. Literature studies show promising results for C-reactive protein (CRP)
as an early marker for postoperative complications, however clinical significance has yet to be determined.
Methods: A multicenter, stepped wedge, prospective clinical trial including all adult patients planned to undergo
elective MAS. The first period consists of standard postoperative monitoring, which entails on demand additional
examinations. This is followed by a period with implementation of postoperative control according to the PRECious
protocol, which implicates standardized measurement of CRP levels. If CRP levels exceed 140 mg/L on
postoperative day 3,4 or 5, an enhanced CT-scan is performed.
Primary outcome in this study is a combined primary outcome, entailing all morbidity and mortality due to
postoperative complications. Complications are graded according to the Clavien-Dindo classification. Secondary
outcomes are hospital length of stay, patients reported outcome measures (PROMs) and cost-effectiveness. Data
will be collected during admission, three months and one year postoperatively. Approval by the medical ethics
committee of the VU University Medical Center was obtained (ID 2015.114).
Discussion: the PRECious trial is a stepped-wedge, multicenter, open label, prospective clinical trial to determine
the effect of a standardized postoperative quality control algorithm on postoperative morbidity and mortality, and
cost-effectiveness.
Trial registration: www.ClinicalTrials.gov, NCT02102217. Registered 5 February 2015.
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Major abdominal surgery (MAS) may be defined as a surgi-
cal resections performed on colorectal, hepato-pancreatico-
biliary and upper gastrointestinal organs with either
primary anastomosis and/or stoma. Around 20 % of all
MAS patients have a major complication, which requires
invasive treatment such as reoperation, percutaneous drain-
age and intensive care admission [1, 2]. Major complica-
tions further increase morbidity and mortality after MAS,
leading to longer intensive care and hospital stay, un-
planned open procedures, creation of stomas and possible
increase in cancer recurrence rates and costs [3–5].
In current postoperative practice median time to clinical
diagnosis of a postoperative complication is approximately
8 days [6–8]. A delay in diagnosis of complications in-
creases morbidity and mortality related to major compli-
cations [9–11], whereas early diagnosis of postoperative
septic complications, before clinical deterioration, is asso-
ciated with a decrease in the associated morbidity and
mortality [12, 13]. Early detection of septic complications
is challenging and may (clinically, serologically and in im-
aging techniques) be hard to distinguish from the physio-
logical and postoperative systemic inflammatory response
syndrome (SIRS) [8, 14, 15]. Furthermore clinical risk as-
sessment appears to have a low predictive value for major
complications such as anastomotic leak [16]. This further
stresses the need for a standardized quality control algo-
rithm after MAS. Notably, there are currently no standard
quality control tests or protocols available for use after
MAS to differentiate between a normal and a complicated
postoperative course.
Several biomarkers, such as Interleukin-6 (IL-6), tumor
necrosis factor α (TNF-α), procalcitonin, white blood cell
count (WBC) and C-reactive protein (CRP) [17], have
been assessed in the search for a marker in the early diag-
nosis of postoperative complications. WBC does not sig-
nificantly differ in patients with an uncomplicated versus
complicated postoperative course. WBC is therefore not
useful in a standardized quality control algorithm. Procal-
citonin, IL-6 and TNF-α have been assessed as markers of
postoperative sepsis [18]. However, compared to CRP they
achieve similar results in predicting major complications
after MAS. Moreover, taking into account the higher cost
and limited availability of procalcitonin, IL-6 and TNF-α
testing [19], further focus will be on the use of CRP in a
postoperative standardized quality control algorithm.
CRP is well-established as a marker of infections and
complications and has shown promising results [19, 20]. It
is an acute-phase protein synthesized in the liver under
stimulation of IL-6 and TNF-α in inflammatory processes,
which amongst others enhances phagocytosis of bacteria
by macrophages [21]. In healthy individuals, the CRP level
is <1 mg/L. In mild inflammation it can rapidly reach over
40 mg/L and even levels >400 mg/L have been detected insevere inflammatory response, sepsis or burns [22]. CRP
levels also increase as a consequence of operative trauma,
and it is even suggested that the level of postoperative
CRP is proportional to the length of the operation,
amount of operative trauma and intra-operative complica-
tions [23]. A peak in postoperative CRP levels is observed
48 − 72 hours after surgery. In uneventful cases, the levels
decrease after this peak [24]. Furthermore, the plasma
half-life of CRP is 19 hours and postoperative CRP levels
are independent of gender, age, body mass index (BMI),
diet, diurnal rhythm or organ function [25]. Circulating
CRP levels are therefore only determined by their rate of
synthesis [26]. Based on these characteristics, CRP might
be a promising valuable marker for grading inflammation
related to postoperative complications.
Several studies have assessed the use of CRP as a marker
for postoperative complications after MAS. Established
cut-off CRP levels serving as markers for infective compli-
cations range from 140 mg/L to 170 mg/L on postopera-
tive day (POD) 3 [27, 28]. In relation to anastomotic
leakage in patients undergoing colorectal surgery, a cutoff
for CRP of 190 mg/L on POD 3 and 125 mg/L on POD 4
has been proposed [29, 30]. The largest retrospective
series included 1,187 patients who had undergone colo-
rectal surgery, calculating a cutoff of 123 mg/L as a
marker for all septic complications [20, 31], yet they did
not differentiate between minor and major complications.
A recent meta-analysis established a cutoff of 172 mg/L
on POD 3 as a marker for anastomotic leakage [32]. Defi-
nitions for anastomotic leak vary widely in the literature
[33], which limits reproducibility and excludes patients
that require re-intervention for other complications.
Therefore, our interest lies in diagnosing all major compli-
cations that require invasive treatment, as classified by
grades 3 − 5 in the Clavien-Dindo classification [34, 35].
Based on our own retrospective data for 399 patients
who underwent MAS, a level of 140 mg/L is proposed
as cutoff for POD 3, 4 and 5 as a marker for major com-
plications, with an overall sensitivity of 78.1 %, a specifi-
city of 53.7 % and a negative predictive value of 89.1 %.
This is in line with recent literature [2, 36].
Serum CRP is non-specific for location, thus, additional
imaging is required. Computed tomography (CT) is the
current imaging modality of choice. In our retrospective
data, CT had sensitivity of 91.7 % and specificity of 100 %
for diagnosis of major complications; this is confirmed in
the literature [14, 37]. Moreover, in the study conducted
by Eckmann et al. CT had sensitivity of 97 % [13]. Another
recent study established CT as the preferred modality in
diagnosis of anastomotic leakage [36].
In 2008, Den Dulk et al. implemented a standardized
scoring system for the clinical status of patients undergo-
ing colorectal surgery. With this system they decreased
the time between surgery and diagnosis of anastomotic
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from 39 % to 24 % (p = 0,24), further supporting the role
of a standardized postoperative quality control algorithm
following MAS [6, 7]. However the search for an optimal
algorithm continues. CRP and CT scanning have been
shown to differentiate between an uncomplicated and a
complicated postoperative course. Currently their use is
only on demand. The PRECious protocol presented here
is a postoperative quality control algorithm, which is
aimed at early diagnosis and treatment of patients with
major complications.Methods
Study objectives
The aim of this study is to evaluate the role of a standard-
ized quality control algorithm after MAS in order to early
diagnose and treat major complications and achieve safe
discharge criteria. The PRECious trial is a prospective,
multicenter, open, stepped-wedge study. All patients who
are planned to undergo elective major digestive surgery,
defined as any gastro-intestinal resection with reconstruc-
tion via anastomosis or stoma, will be included. Our hy-
pothesis is that the standardized postoperative quality
control algorithm will allow for early diagnosis and treat-
ment of complications, thereby decreasing morbidity and
mortality associated with MAS.Endpoints
The primary endpoint of the study consists of a com-
bined endpoint entailing all morbidity and mortality due
to major complications. Complications will be classified
according to a modified Clavien-Dindo classification in
two groups [34, 35]. Group I consists of grade I and
grade II complications, which are classified as minor.
Early detection of major complications that may require
invasive treatment, such as re-laparotomy or percutan-
eous drainage and/or intensive care admission, which
might even lead to death, as classified by Clavien-Dindo
grades III, IV and V, is of major importance. The com-
prehensive complication index will also be calculated
[38]. All mortality and morbidity after major complications
will be recorded, entailing fistula; bowel obstruction or her-
niation; abscesses; wound dehiscence; abdominal compart-
ment syndrome; unplanned enterostomy; enterostomy
dysfunction; myocardial infarction; pulmonary embolism;
respiratory insufficiency; urosepsis; cerebrovascular acci-
dent; bleeding, and anastomotic leak.
Secondary endpoints will be patient-related outcome
measures (PROMs), measured with the EuroQol-5D
(EQ-5D) and gastrointestinal quality of life index
(GIQLI) questionnaires. Furthermore postoperative re-
covery data will be collected in both groups, such as
length of hospital stay and intensive care length of stay.Alongside the trial a cost-effectiveness analysis will be
conducted.
Power of the study
Based on retrospective data of 399 patients who under-
went MAS, we assessed all mortality and morbidity due to
major complications (multiple reoperations, multiple per-
cutaneous drainages, enterostomy during re-intervention)
and found this to be 17 %. Based on the results of den
Dulk, who report a decrease in mortality following imple-
mentation of a clinical item scoring list, we calculated the
following sample size [6]: a group sample size of 525 in
group 1 and 525 in group 2 to achieve 80 % power to de-
tect a difference in frequency of morbidity in the control
group, which is 17 %, in comparison to the PRECious
group, with an expected morbidity of 11 %. The test statis-
tic used is the two-sided Mantel-Haenszel test. The sig-
nificance level of the test was targeted at 0.05.
Inclusion criteria
All adult patients who are to undergo elective MAS can
be included in the study. MAS will be defined as all
gastrointestinal resections with reconstruction with anas-
tomosis and/or stoma. For instance, cholecystectomy will
not be included because no anastomosis or stoma is per-
formed. Written informed consent will be obligatory.
Exclusion criteria
Patients who undergo emergency surgery as a primary
operation will be excluded to allow for appropriate in-
formed consent. Patients with an American Society of
Anaesthesiologists (ASA) classification of four of higher
will be excluded. As CT may be performed if CRP levels
exceed 140 mg/L, patients with pre-operative impaired
renal function (glomerular filtration rate <60) (within
4 weeks before surgery) will be excluded. Also patients
with allergy to contrast medium will be excluded.
Participating surgeons and clinics
Seven Dutch hospitals will participate in the study; one
academic and six teaching centers: VU medical center,
Amsterdam; Slotervaart ziekenhuis, Amsterdam; Medisch
Centrum Alkmaar, Alkmaar; Rode Kruis Ziekenhuis,
Beverwijk; Spaarne Gasthuis, Haarlem; Westfries
Gasthuis, Hoorn and Zaans Medisch Centrum, Zaandam.
All participating surgeons have ample experience
within their respective field. This is of importance be-
cause complication rates and morbidity are associated
with learning curves and might therefore affect the
primary outcome [39].
Patient allocation and design
Patients will be informed about the study at the outpatient
clinic. The patient will be included upon admission after
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the study, a parallel-randomized design is not the pre-
ferred option, because this would allow for bias by cross-
over and automated CRP and CT enquiries by physicians
in both patient groups. A cluster design is not deemed
feasible due to differences between the participating cen-
ters (i.e., academic and teaching hospitals). A stepped-
wedge design is deemed appropriate. Due to the large
number of participating centers, little bias is expected
from other changes in treatment. Changes will be moni-
tored and corrected for if applicable. Thus, the two groups
will be compared according to two periods. Patients allo-
cated to the first period will receive standard on-demand
additional examinations. After a transition phase of one
month allowing for implementation, all patients will be al-
located to the intervention arm and will receive standard-
ized postoperative monitoring of serum CRP levels on
POD 3, 4 and 5. If CRP levels exceed 140 mg/L additional
CT will be conducted.
Data collection will be via an online module, which al-
lows for inclusion and data collection. Participating sur-
geons will be able to log in to the secured module via the
PRECious trial website. After completing the inclusion
form, an immediate response with a code number and
type of postoperative control protocol will be obtained.
The nature of the study does not allow for blinding,
because it would not be ethical to perform sham venous
puncture, and the protocol will be known by the attend-
ing physician to allow CT to be arranged. Instead of
blinding, the add-on value of CRP measurements will be
tested. The attending physician will have to grade the
patient in the morning before CRP levels are known,
grade 1 indicating a healthy patient, grade 10 a patient
at acute risk of death. The physician will also have to
state whether he/she would perform CT prior to CRP
levels being measured, allowing for assessment of the
add-on value of the presented standardized quality con-
trol algorithm.
Data collection and statistics
Data will be collected partially by means of a secured
Internet module and partially by hard-copy datasheets.
The secured online module is especially designed for the
PRECious trial. Hard-copy datasheets, such as completed
quality of life questionnaires will be sent to the VU med-
ical center by mail, were they will be kept in a secured
room. Data will be collected daily until discharge. PROMs
will be collected preoperatively, and at 5 days, 3 months
and 12 months postoperatively. A study chart for mea-
surements is depicted in Table 1.
One research fellow in the VU medical center will moni-
tor the data for all included patients, and maintain regular
contact with all participating centers. Due to the nature of
the study the researcher cannot be blinded, hence anexternal monitoring committee (Clinical Research Bureau,
Amsterdam, Netherlands) is installed and will assess data
collection. All required parameters will be collected in an
SPSS data file. Data analysis will be performed according
to the intention-to-treat principle. Continuous variables
will be compared using the t test or Mann-Whitney U
test, as appropriate. Frequencies will be compared using
the Chi-square or McNemar tests, as appropriate.
Economic evaluation
Direct medical costs, non-medical costs and time-cost
differences will be calculated for each arm of the study.
These will include the increased costs in the PRECious
arm due to the extra CRP testing and greater use of CT,
and costs due to complications and readmissions. We
expect admission duration to be shorter in the PRECious
arm due to early diagnosis and treatment of complica-
tions. Therefore, the protocol committee deems the proto-
col cost-effective. On retrospective analysis of direct
medical costs in patients who underwent MAS the aver-
age cost was 8.584,81 € (95 % CI 8.332,51 − 8.860,81 €) in
patients without complications, 15.412,96 € (95 % CI
14.250,22 − 16.708,82 €) after minor complications, and
29.198,23 € (95 % CI 27.187,13 − 31.295, 78 €) in patients
with a major complication that required invasive treat-
ment (p <0.001) [5].
Ethics
The study will be conducted in accordance with the
principles of the Declaration of Helsinki and Good
Clinical Practice guidelines. The protocol has been
written in concordance with the SPIRIT guidelines, as
depicted in the checklist (see Additional file 1) [40].
The scientific research committee of the Cancer Center
Amsterdam, the Netherlands, approved the study on 12
March 2014 (ID: Pro 14/23). Approval by the medical
ethics committee of the VU University Medical Center,
Amsterdam was obtained on 26 May 2015 (Protocol ID
2015.114 – NL43534.029.15). The board of executives
in each participating center will have to approve the
final protocol (version 2.0, 4 May 2015) prior to the
start of inclusions. Written informed consent will be
obtained from all participating patients. This trial was




Patients in both groups will receive similar preoperative
treatment. Standard anti-thrombotic prophylaxis will be
administered according to the local protocol. Further-
more, standard prophylactic antibiotics will be adminis-
tered according to the local protocol.
Table 1 Study measurements
Study period
Enrolment Allocation Post-allocation Close-out







CRP measurement X X X X
QOL questionnaire X X X X
PRECious group
CRP measurement X X X X
CT if CRP >140 mg/L X X X
QOL questionnaire X X X
Assessments
Control group
List baseline variables X
List operative data X
List admission data X
Quality of life X X X X
List morbidity X X X
List survival X X X
PRECious group
List baseline variables X
List operative data X
List admission data X
Quality of life X X X X
List morbidity X X X
List survival X X X X
POD postoperative day, Mo months, CRP C-reactive protein, CT computed tomography scan, QOL Quality of Life, Tx end of protocol
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In the first period all patients will be allocated to the
control group and will receive standard postoperative
monitoring, which consists of daily measurement of clin-
ical parameters (heart rate, blood pressure, temperature,
pain) and assessment of the patient by the attending
physician. Additional examinations such as blood sam-
pling and imaging will only be conducted on demand,
for instance, if clinical parameters deviate or physical
examination shows signs of complications.
PRECious group
The second period will be considered the intervention
group. All patients will be allocated to postoperative con-
trols according to the PRECious protocol. Within thisprotocol peripheral blood samples for CRP measurements
will be collected routinely on POD 2, 3, 4 and 5. If CRP
exceeds 140 mg/L on the third, fourth or fifth POD, en-
hanced CT of the abdomen will be conducted within
24 hours. It is expected that two thirds of patients will
undergo CT versus one third of the control group. Intra-
venous contrast is administered, with regard to renal func-
tion, to conduct CT. Depending on the organ undergoing
surgery, oral or rectal contrast will be administered, for
which the patient will have to drink oral contrast or re-
ceive rectal administration prior to CT. After the first
postoperative week, CRP samples will be collected on de-
mand, according to the consulting physician. If a major
complication is diagnosed, immediate treatment will be
commenced as soon as possible and as appropriate. All
Straatman et al. Trials  (2015) 16:382 Page 6 of 8major complications are to be confirmed in reoperation or
suspicious drain fluid upon percutaneous drainage and
culture.
To allow for correct implementation of the protocol a
transition period of month is deemed necessary before
starting measurements in the intervention group. A
flow-chart depicting the design of the study is displayed
in Fig. 1.Postoperative management
Besides differences in postoperative controls, postopera-
tive management will be similar in both groups. Early
mobilization will be encouraged, starting with sitting out
of bed the first day postoperatively. A dietician will moni-
tor intake. Patients will be discharged when they pass
stools, are able to drink and eat sufficiently and are com-
fortable with oral analgesia. Follow up will be scheduled at
the outpatient clinic 3 and 12 months after the index op-
eration. Here PROMs will be collected and morbidity
monitored.Fig. 1 Flow chart for the stepped wedge design of the PRECious trial. ASA
rate, PROMs=Patient Reported Outcome Measures, POD=Postoperative dayDiscussion
In an era of advancements in surgical techniques and fast-
track care, both modalities aiming to decrease morbidity and
mortality after major abdominal surgery, there is currently
no postoperative quality control algorithm available. A qual-
ity control algorithm should aim at safe discharge and early
diagnosis and treatment of complications [10, 12]. Den Dulk
et al. demonstrated a decrease in the time taken to diagnose
anastomotic leakage, by implementing a leakage score.
Although no significant difference in mortality rates was
observed (39 % versus 24 %; p= 0.24), their research supports
the use of a postoperative quality control algorithm, although
the optimal algorithm is yet to be determined [6, 7].
CRP has shown promising in multiple observational
studies, with an optimal cutoff in our observational co-
hort study of 399 patients of 140 mg/L on the third
POD [8, 20, 23, 27–29, 31, 41]. Information on the pre-
dictive value of dynamic changes in CRP is not available,
but will be monitored, comparing the levels on POD 2
to 5. POD 1 levels are not measured, because a peak is
not observed until POD 2 [23].=Americal Society of Aneasthesiologist score, GFR=Glomerular filtration
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on diagnosis of postoperative complications has yet to be
determined. Here we propose a standardized postoperative
quality control algorithm including repeated CRP mea-
sures and additional CT if CRP levels exceed 140 mg/L on
the third, fourth and fifth POD [2]. Aiming for a decrease
in morbidity and mortality associated with major compli-
cations after major abdominal surgery a prospective, ran-
domized study is deemed necessary.
Trial status
The scientific research committee approved the design
of the PRECious-trial. Approval by the medical ethics
committee of the VU University Medical Center,
Amsterdam was obtained on 26 May 2015 (Protocol
ID 2015.114 – NL43543.029.15). The trial is not yet
recruiting.
Additional file
Additional file 1: SPIRIT item checklist. Checklist that addresses the
separate items of the SPIRIT guidelines and where they are listed in the
manuscript. (DOC 132 kb)
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